Story highlights
- New US graphene start up launched
- New product is a low-cost biosensor for small molecule and protein analysis
- Commercial release is planned for early 2016
(2D Materials Magazine)- A new start up, Nanomedical Diagnostics, Inc., will develop and commercialize graphene-based bioelectronics for use in research and diagnostics.
The company’s first product, AGILE Research, a label-free, quantitative, low-cost biosensor for small molecule and protein analysis,. The product will enter beta testing soon and commercial release is scheduled for early 2016, for research use only.
AGILE Research is based on graphene biological field effect transistor (BioFET) technology. The company is currently focused on finalizing AGILE Research product design and will be evaluating its performance with the Centers for Disease Control and Prevention (CDC) and Stanford University. The CDC and Nanomedical Diagnostics are entering into a Cooperative Research and Development Agreement to evaluate direct electronic detection of Borrelia burgdorferi antigens for a new Lyme disease diagnostic system. Lyme disease research is also a focal point in the Stanford beta test.
For more information about Nanomed or AGILE Research, including pre-order opportunities, visit http://www.nanomedicaldiagnostics.com.
